Table 2.

Specimens referred for clinical genotyping

	No. (%)
Specimens referred for BRAF, HER2 and PIKC3CA mutational analysis	427 (100)
Specimens that did not complete genetic analysis	83 (19)
Insufficient tumor material for genotyping; testing not performed*	34 (8)
Insufficient tumor material for conclusive results; testing performed†	22 (5)
Failed PCR amplification	15 (4)
Incomplete testing at all predefined exons of BRAF, HER2 and/or PIK3CA	6 (1)
Specimen could not be located	6 (1)
Specimens successfully tested for BRAF, HER2 and PIK3CA mutations	344 (81)

^*Insufficient tumor material for genotyping identified during pathology pre-review.

^†Twenty-two specimens were found to be wild-type for BRAF, HER2, and PIK3CA but were classified as inconclusive because there was less than 50% malignant tissue in the specimen.